{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-036940","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.152146+00:00","generated_at":"2026-05-31T09:40:50.619208+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PDS Biotech Q2 net loss narrows to $8.3M; FDA aligned on Phase 3 trial for Versamune HPV in HNSCC","bullets":["Net loss $8.3M ($0.23/share) vs $11.5M ($0.37/share) YoY; R&D expenses down 44% to $4.5M.","Cash and equivalents $57.7M as of June 30, 2024.","FDA alignment achieved on Phase 3 VERSATILE-003 trial design for Versamune HPV + pembrolizumab; start Q4 2024.","Updated VERSATILE-002 data shows median OS of 30 months; abstracts accepted at ESMO, ASTRO, ICIS 2024.","Total operating expenses reduced to $8.7M from $12.7M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-036940","json":"https://secwatch.observer/filing/0001140361-24-036940.json","markdown":"https://secwatch.observer/filing/0001140361-24-036940.md","text":"https://secwatch.observer/filing/0001140361-24-036940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124036940/0001140361-24-036940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124036940/ef20034030_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:40:50.619208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}